Vanda Pharmaceuticals (VNDA) Competitors $4.71 +0.05 (+1.07%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$4.75 +0.04 (+0.85%) As of 09:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA vs. OPK, GERN, ZBIO, RGLS, LXRX, MYGN, EBS, RIGL, XOMA, and VSTMShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include OPKO Health (OPK), Geron (GERN), Zenas BioPharma (ZBIO), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), and Verastem (VSTM). These companies are all part of the "biotechnology" industry. Vanda Pharmaceuticals vs. Its Competitors OPKO Health Geron Zenas BioPharma Regulus Therapeutics Lexicon Pharmaceuticals Myriad Genetics Emergent Biosolutions Rigel Pharmaceuticals XOMA Royalty Verastem OPKO Health (NASDAQ:OPK) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Which has higher valuation and earnings, OPK or VNDA? Vanda Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOPKO Health$713.10M1.53-$53.22M-$0.07-19.71Vanda Pharmaceuticals$198.77M1.40-$18.90M-$0.75-6.28 Do analysts recommend OPK or VNDA? OPKO Health presently has a consensus price target of $2.75, indicating a potential upside of 99.28%. Vanda Pharmaceuticals has a consensus price target of $16.50, indicating a potential upside of 250.32%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than OPKO Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OPKO Health 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media favor OPK or VNDA? In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than OPKO Health. MarketBeat recorded 1 mentions for Vanda Pharmaceuticals and 0 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.00 equaled Vanda Pharmaceuticals'average media sentiment score. Company Overall Sentiment OPKO Health Neutral Vanda Pharmaceuticals Neutral Which has more risk & volatility, OPK or VNDA? OPKO Health has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Is OPK or VNDA more profitable? OPKO Health has a net margin of -5.66% compared to Vanda Pharmaceuticals' net margin of -21.98%. OPKO Health's return on equity of -2.85% beat Vanda Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets OPKO Health-5.66% -2.85% -1.82% Vanda Pharmaceuticals -21.98%-8.30%-6.85% Do institutionals and insiders believe in OPK or VNDA? 64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by insiders. Comparatively, 8.9% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryOPKO Health beats Vanda Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$274.64M$2.92B$5.48B$9.44BDividend YieldN/A2.49%4.01%4.02%P/E Ratio-6.2820.5328.2919.90Price / Sales1.40265.95413.9185.75Price / CashN/A41.6635.9658.29Price / Book0.517.808.345.67Net Income-$18.90M-$55.10M$3.24B$258.18M7 Day Performance-2.08%4.62%3.14%2.81%1 Month Performance5.37%17.99%10.99%13.53%1 Year Performance-25.24%2.21%34.16%17.68% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals4.6147 of 5 stars$4.71+1.1%$16.50+250.3%-25.7%$274.64M$198.77M-6.28290News CoverageUpcoming EarningsOPKOPKO Health3.6193 of 5 stars$1.40+3.7%$2.75+96.4%-5.5%$1.07B$713.10M-20.002,997GERNGeron3.4597 of 5 stars$1.23-0.8%$4.61+274.9%-72.6%$789.78M$76.99M-5.8670Analyst RevisionZBIOZenas BioPharma1.1214 of 5 stars$14.29+4.1%$36.67+156.6%N/A$574.38M$5M0.00N/ARGLSRegulus Therapeutics1.7337 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830LXRXLexicon Pharmaceuticals2.5342 of 5 stars$1.23flat$3.67+198.1%-43.1%$444.64M$31.08M0.00140Upcoming EarningsMYGNMyriad Genetics4.5096 of 5 stars$4.45-0.4%$14.38+223.2%-83.5%$412.03M$837.60M0.002,700EBSEmergent Biosolutions3.9128 of 5 stars$6.93+0.0%$14.33+106.8%-37.6%$376.14M$1.04B-2.562,420RIGLRigel Pharmaceuticals3.2426 of 5 stars$19.59+4.2%$36.40+85.8%+98.4%$336M$179.28M9.08160News CoveragePositive NewsXOMAXOMA Royalty3.8441 of 5 stars$25.48-0.7%$69.50+172.8%-11.0%$307.19M$28.49M0.0010VSTMVerastem3.2985 of 5 stars$5.10-1.2%$13.38+162.3%+54.1%$283.54M$10K0.0050 Related Companies and Tools Related Companies OPKO Health Competitors Geron Competitors Zenas BioPharma Competitors Regulus Therapeutics Competitors Lexicon Pharmaceuticals Competitors Myriad Genetics Competitors Emergent Biosolutions Competitors Rigel Pharmaceuticals Competitors XOMA Royalty Competitors Verastem Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VNDA) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
